Medical Condition News

RSS

PLC Systems' RenalGuard to be utilized in a live case transmission at the GISE 2009 conference

PLC Systems Inc., a company focused on innovative cardiac and vascular medical device-based technologies, today announced that its RenalGuard System(TM) will be utilized as part of a live case transmission from the Clinica Mediterranea, Naples, Italy, to the 30th Congresso Nazionale della Societa' Italiana di Cardiologia Invasiva (GISE) during the conference.

19 Oct 2009

Metabolic master switch sets the biological clock in body tissues

Our body's activity levels fall and rise to the beat of our internal drums-the 24-hour cycles that govern fundamental physiological functions, from sleeping and feeding patterns to the energy available to our cells. Whereas the master clock in the brain is set by light, the pacemakers in peripheral organs are set by food availability. The underlying molecular mechanism was unknown.

19 Oct 2009

Campaign to educate men and women about fibromyalgia

Women and men have opposing views on many topics, and it turns out that they also have different takes on chronic pain.

19 Oct 2009

Antisense Pharma's SAPPHIRE Phase III trial evaluating trabedersen approved by Health Canada

The biopharmaceutical company Antisense Pharma GmbH has announced today that it has received the approval by Health Canada for its pivotal Phase III clinical trial SAPPHIRE in patients with recurrent or refractory anaplastic astrocytoma.

19 Oct 2009

Oral salmon calcitonin using absorption-enhancing Eligen Technology holds promise for osteoarthritis

Emisphere Technologies, Inc. announced study results in which twice-daily oral salmon calcitonin using Emisphere’s proprietary Eligen® Drug Delivery Technology significantly suppressed markers of cartilage and bone degradation versus placebo in men and women with osteoarthritis, the most common form of arthritis.

19 Oct 2009

Rich Plasma and Stem Cell therapies improve orthopedic conditions

Although stem cells sounds innovative and cutting edge, this therapy has been around for quite some time. In today's advanced medical climate stem cells are being used to treat many orthopedic conditions including osteoarthritis of the hip knee and shoulder, partial tears of tendons, muscles, and ligaments including rotator cuff tears, and various back conditions including disc herniations.

19 Oct 2009

Chinese SFDA approves China Medical Technologies' SPR System

China Medical Technologies, Inc., a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic products, today announced that the Company has received approval for its SPR- based analysis system (the "SPR System") from the State Food and Drug Administration of China (the "SFDA").

19 Oct 2009

Talecris Biotherapeutics' PROLASTIN-C receives FDA approval

Talecris Biotherapeutics (Nasdaq: TLCR) today received approval from the U.S. Food and Drug Administration for PROLASTIN®-C (Alpha1-Proteinase Inhibitor [Human]), a more concentrated version of PROLASTIN® produced using advances in manufacturing technology.

19 Oct 2009

Genentech reports results of ACTEMRA Phase III study for rheumatoid arthritis

Genentech, Inc., a wholly-owned member of the Roche Group, today announced two-year results from a Phase III study, which showed that people with rheumatoid arthritis (RA) who received either a 4 mg/kg or 8 mg/kg dose of ACTEMRA® (tocilizumab), in combination with methotrexate, had no progression of joint damage, (75 and 83 percent, respectively, as assessed by radiograph) compared with people who received methotrexate alone (66 percent).

19 Oct 2009

Angiochem reports Phase 1/2 efficacy study results of ANG1005 for treating brain cancer

Angiochem, Inc. a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier to treat brain diseases, announced today that its lead drug candidate, ANG1005, has demonstrated a favorable safety and efficacy profile in more than 100 patients with brain cancer from two separate Phase 1 /2 clinical studies in patients with progressive gliomas, including recurrent glioblastoma, and in patients with progressive brain metastases.

19 Oct 2009

AstraZeneca's CRESTOR approved for treating pediatric patients with HeFH

AstraZeneca today announced the U.S. Food and Drug Administration (FDA) approved CRESTOR® (rosuvastatin calcium) for use in pediatric patients ages 10-17 with heterozygous familial hypercholesterolemia (HeFH) when diet therapy fails to reduce elevated cholesterol. HeFH, a genetic disease, is characterized by high LDL cholesterol (the "bad" cholesterol) and increased risk of early cardiovascular disease.

19 Oct 2009

New decision-making tool offers breast reconstruction options post cancer surgery

A computer-based decision-making aid may make it possible for more women to have breast reconstruction after surgical treatment for cancer.

19 Oct 2009

Research study on EGFR and HER2 expressions in BTC

The epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor 2 (HER2) are involved in the carcinogenesis of many malignancies. Therapeutic molecules targeting EGFR and HER2 have been successfully used for the treatment of colorectal, breast, lung and head and neck cancers among others.

19 Oct 2009

IAVI and Ragon Institute sign MOU to devise new vaccine strategies for AIDS

The International AIDS Vaccine Initiative (IAVI) announced today that it has signed a memorandum of understanding with the Ragon Institute to accelerate the development of new and promising AIDS vaccine candidates for testing.

19 Oct 2009

QLT receives exclusive U.S. sales and marketing rights for Visudyne therapy

QLT Inc. ("QLT" or the "Company") today announced that it has restructured its agreement with Novartis Pharma AG ("Novartis") to simplify the relationship, under which, effective January 1, 2010, it will, among other things, receive exclusive U.S. rights to the Visudyne(R) patents to sell and market Visudyne in the U.S. Visudyne, a photosensitizer co-developed with Novartis, is approved worldwide for the treatment of a form of wet age-related macular degeneration ("AMD"), the leading cause of legal blindness in people over the age of 55 in North America and Europe.

19 Oct 2009

Lubricin injections can reduce cartilage degeneration

Medical researchers will report findings today (Oct. 19) that demonstrate that injecting the protein lubricin into knee joints can dramatically reduce cartilage degeneration.

19 Oct 2009

Copper bracelets and magnetic wrist straps are ineffective in relieving arthritis pain, says study

Copper bracelets and magnetic wrist straps are ineffective in relieving arthritis pain, according to a new study led by a University of York academic.

19 Oct 2009

Anti-clotting drug may cause problems for elderly trauma patients: Study

A common drug used for preventing heart attacks and blood clots may also cause problems for individuals who suffer some form of trauma, particularly elderly patients, according to a study presented today at the 2009 Clinical Congress of the American College of Surgeons.

19 Oct 2009

New mathematical model for rapid and accurate diagnoses of AHF

Researchers at St. Michael's Hospital have developed the first mathematical model in cardiology and emergency medicine to more quickly and reliably diagnose acute heart failure (AHF) in emergency room patients

19 Oct 2009

Readmission of elderly patients after colectomy strongly linked with mortality: Study

Readmission to a hospital after standard surgical treatment for colon cancer is far more common than suspected for elderly patients according to researchers who presented their findings at the 2009 Clinical Congress of the American College of Surgeons. Results from the first study to determine nationwide readmission rates following colectomy [surgical removal of malignant disease and part of the colon] in the Medicare population revealed that nearly one in nine patients over the age of 65 was readmitted within 30 days.

19 Oct 2009